|
|
Volumn 71, Issue 8, 2008, Pages 615-616
|
|
How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BETA INTERFERON;
GLATIRAMER;
INTERFERON;
NEUROPROTECTIVE AGENT;
PEPTIDE;
DISABILITY;
DISABILITY SEVERITY;
DISEASE COURSE;
DRUG EFFICACY;
HUMAN;
LETTER;
MULTIPLE SCLEROSIS;
NEUROPROTECTION;
OUTCOME ASSESSMENT;
PRIORITY JOURNAL;
TREATMENT OUTCOME;
DRUG SAFETY;
MEDICAL LITERATURE;
TREATMENT DURATION;
DOSE RESPONSE;
METHODOLOGY;
NOTE;
DISABILITY EVALUATION;
DISEASE PROGRESSION;
DOSE-RESPONSE RELATIONSHIP, DRUG;
HUMANS;
INTERFERONS;
MULTIPLE SCLEROSIS, RELAPSING-REMITTING;
NEUROPROTECTIVE AGENTS;
PEPTIDES;
RESEARCH DESIGN;
TREATMENT OUTCOME;
|
|
EID: 54749130030
PISSN: 00283878
EISSN: 1526632X
Source Type: Journal
DOI: 10.1212/01.wnl.0000324708.37575.5c Document Type: Letter |
|
Times cited : (1)
|
|
References (3)
|
